Howard Robin Biography and Net Worth

Howard W. Robin is President, Chief Executive Officer, Director of the Company. Mr. Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a director. From 1991 to 2001, Mr. Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc. (Berlex), a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer of Berlex. From 1984 to 1987, Mr. Robin was Director of Business Planning and Development at Berlex. He was a Senior Associate with Arthur Andersen & Co. prior to joining Berlex. Mr. Robin serves as a director of the Biotechnology Industry Organization, the world’s largest biotechnology industry trade organization, and also serves as a director of BayBio, a non-profit trade association serving the Northern California life sciences community. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University in 1974.

What is Howard W. Robin's net worth?: The estimated net worth of Howard W. Robin is at least $3.12 million as of November 25th, 2025. Mr. Robin owns 54,245 shares of Nektar Therapeutics stock worth more than $3,123,970 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Robin may own. Additionally, Mr. Robin receives a salary of $1,830,000.00 as CEO at Nektar Therapeutics. Learn More about Howard W. Robin's net worth.
How old is Howard W. Robin?: Mr. Robin is currently 71 years old. There are 4 older executives and no younger executives at Nektar Therapeutics. Learn More on Howard W. Robin's age.
What is Howard W. Robin's salary?: As the CEO of Nektar Therapeutics, Mr. Robin earns $1,830,000.00 per year. Learn More on Howard W. Robin's salary.
How do I contact Howard W. Robin?: The corporate mailing address for Mr. Robin and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected]. Learn More on Howard W. Robin's contact information.
Has Howard W. Robin been buying or selling shares of Nektar Therapeutics?: Within the last three months, Howard W. Robin has sold $119,795.96 in shares of Nektar Therapeutics stock. Most recently, Howard W. Robin sold 2,207 shares of the business's stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $54.28, for a transaction totalling $119,795.96. Following the completion of the sale, the chief executive officer now directly owns 54,245 shares of the company's stock, valued at $2,944,418.60. Learn More on Howard W. Robin's trading history.
Who are Nektar Therapeutics' active insiders?: Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Roy Whitfield (Director), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.
Are insiders buying or selling shares of Nektar Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 43,135 shares worth more than $1,344,931.62. The most recent insider tranaction occured on November, 25th when insider Jonathan Zalevsky sold 1,157 shares worth more than $62,801.96. Insiders at Nektar Therapeutics own 3.7% of the company. Learn More about insider trades at Nektar Therapeutics.
Information on this page was last updated on 11/25/2025.

Howard W. Robin Insider Trading History at Nektar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/25/2025	Sell	2,207	$54.28	$119,795.96	54,245
9/9/2025	Sell	6,666	$46.69	$311,235.54	49,342
9/5/2025	Sell	6,666	$38.53	$256,840.98	56,008
9/4/2025	Sell	5,166	$33.70	$174,094.20	62,674
9/2/2025	Sell	1,500	$30.16	$45,240.00	67,840
8/19/2025	Sell	1,573	$26.59	$41,826.07	69,340
5/19/2025	Sell	1,547	$10.05	$15,547.35	70,912
2/19/2025	Sell	1,584	$15.15	$23,997.60	72,460
12/17/2024	Sell	3,133	$15.15	$47,464.95	79,714
11/19/2024	Sell	1,085	$15.15	$16,437.75	55,472
8/19/2024	Sell	992	$19.20	$19,046.40	56,557
5/17/2024	Sell	1,110	$26.25	$29,137.50	57,549
2/20/2024	Sell	1,335	$10.20	$13,617.00	58,659
11/17/2023	Sell	1,325	$7.35	$9,738.75	59,994
8/16/2023	Sell	1,333	$11.70	$15,596.10	61,319
5/16/2023	Sell	1,357	$10.80	$14,655.60	62,653
2/16/2023	Sell	1,309	$45.00	$58,905.00	64,010
11/16/2022	Sell	2,534	$53.55	$135,695.70	65,319
8/16/2022	Sell	917	$71.40	$65,473.80	67,853
5/16/2022	Sell	2,435	$59.25	$144,273.75	41,396
2/16/2022	Sell	832	$164.25	$136,656.00
8/16/2021	Sell	767	$207.45	$159,114.15	28,274
5/17/2021	Sell	770	$274.50	$211,365.00	29,042
2/3/2021	Sell	10,000	$295.80	$2,958,000.00	40,579
8/17/2020	Sell	792	$295.05	$233,679.60	24,267
2/18/2020	Sell	563	$335.25	$188,745.75	25,658
11/18/2019	Sell	903	$269.55	$243,403.65	19,947
10/16/2019	Sell	2,222	$262.20	$582,608.40	23,073
8/16/2019	Sell	836	$272.25	$227,601.00	18,851
7/24/2019	Sell	2,222	$481.65	$1,070,226.30	21,910
5/23/2019	Sell	6,666	$495.00	$3,299,670.00	21,910
5/21/2019	Sell	2,222	$493.95	$1,097,556.90	21,910
5/16/2019	Sell	892	$470.55	$419,730.60	19,688
2/21/2019	Sell	7,258	$632.85	$4,593,225.30	23,394
2/19/2019	Sell	2,814	$634.95	$1,786,749.30	23,394
11/16/2018	Sell	1,021	$573.75	$585,798.75	16,609
6/27/2018	Sell	8,666	$742.80	$6,437,104.80	17,846
6/25/2018	Sell	2,888	$777.30	$2,244,842.40	17,846
5/16/2018	Sell	852	$1,250.85	$1,065,724.20	14,957
5/3/2018	Sell	8,666	$1,260.75	$10,925,659.50	18,698
5/1/2018	Sell	2,888	$1,254.75	$3,623,718.00	18,698
2/16/2018	Sell	852	$1,244.10	$1,059,973.20	15,809
1/22/2018	Sell	5,555	$1,137.30	$6,317,701.50	22,217
12/13/2017	Sell	5,555	$835.35	$4,640,369.25	18,184
11/1/2017	Sell	5,555	$353.55	$1,963,970.25	15,722
10/9/2017	Sell	5,555	$363.00	$2,016,465.00
9/6/2017	Sell	5,555	$323.10	$1,794,820.50	15,722
8/16/2017	Sell	6,114	$288.90	$1,766,334.60	10,166
5/16/2017	Sell	559	$293.25	$163,926.75	10,725
2/16/2017	Sell	575	$197.10	$113,332.50	11,284
2/8/2017	Sell	5,833	$195.60	$1,140,934.80	17,693
1/17/2017	Sell	5,833	$185.25	$1,080,563.25	17,693
11/17/2016	Sell	6,230	$208.20	$1,297,086.00	8,193
10/4/2016	Sell	5,833	$255.90	$1,492,664.70
9/1/2016	Sell	5,833	$267.45	$1,560,035.85
8/16/2016	Sell	787	$263.40	$207,295.80
5/17/2016	Sell	144	$203.70	$29,332.80	1,273
2/17/2016	Sell	143	$178.80	$25,568.40	898
2/10/2016	Sell	4,444	$172.35	$765,923.40	666
1/19/2016	Sell	4,444	$211.80	$941,239.20	666
12/3/2015	Sell	8,333	$238.05	$1,983,670.65	666
11/11/2015	Sell	8,333	$202.80	$1,689,932.40	666
10/6/2015	Sell	8,333	$164.85	$1,373,695.05	666
9/23/2015	Sell	8,333	$195.60	$1,629,934.80	666
8/13/2015	Sell	3,888	$163.35	$635,104.80
7/14/2015	Sell	3,888	$176.70	$687,009.60
12/1/2014	Sell	23,333	$255.15	$5,953,414.95
11/25/2014	Sell	40,000	$228.75	$9,150,000.00
11/24/2014	Sell	8,853	$225.30	$1,994,580.90

Howard W. Robin Buying and Selling Activity at Nektar Therapeutics

Nektar Therapeutics Company Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Today's Range

Now: $57.69

$54.75

$57.86

50 Day Range

MA: $58.84

$53.95

$65.69

2 Week Range

Now: $57.69

$6.45

$66.92

Volume

475,955 shs

Average Volume

649,746 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Howard Robin Biography and Net Worth

What is Howard W. Robin's net worth?

How old is Howard W. Robin?

What is Howard W. Robin's salary?

How do I contact Howard W. Robin?

Has Howard W. Robin been buying or selling shares of Nektar Therapeutics?

Who are Nektar Therapeutics' active insiders?

Are insiders buying or selling shares of Nektar Therapeutics?